Corrigendum to “Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies” [Biomed. Pharmacother. 150 (2022) 112949] - 30/05/23

Li-ping Zhao ^{a, b, c, d}, Jun-hu Hu ^{a, b, c, d}, Die Hu ^{a, b, c, d}, Hao-jie Wang ^{a, b, c, d}, Chang-gang Huang ^{a, b, c, d}, Ru-hua Luo ^{a, b, c, d}, Zhao-huang Zhou ^{a, b, c, d}, Xin-yun Huang ^{e, ⁎}, Tian Xie ^{a, b, c, d, ⁎} , Jian-shu Lou ^{a, b, c, d, ⁎}

^a School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China 

^b Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China 

^c Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Zhejiang 311121, China 

^d Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China 

^e Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA 

^⁎Corresponding author.^⁎⁎Corresponding authors at: School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang 311121, China.School of Pharmacy, Hangzhou Normal UniversityHangzhouZhejiang311121China

Le texte complet de cet article est disponible en PDF.